Nexalin Technology, Inc. (NXL)
Company Description
Nexalin Technology designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.
We have developed an easy-to-administer medical device — referred to as Gen-1 – that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
This device emits our original waveform at 4 milliamps during treatment and is classified by the FDA as a Class II device. While this device had been cleared by the FDA to treat anxiety and insomnia, we have voluntarily suspended marketing efforts on the Gen-1 device for treatment of anxiety or insomnia until a 510(k) application is approved by the FDA.
We have also already begun designing and developing new advanced waveform technology to be emitted at 15 milliamps through our existing medical device improved with a modern enclosure—referred to as Gen-2— which can penetrate deeper into the brain and the associated structures of mental illness, which we believe will generate enhanced patient response.
Gen-2 is presently being tested in clinical trials, for anxiety, insomnia and depression in the United States and China.
| Country | United States |
| Founded | 2010 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 2 |
| CEO | Mark White |
Contact Details
Address:
1776 Yorktown, Suite 550 Houston, TX 77056 United States | |
| Phone | (713) 660-1100 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1527352 |
Key Executives
| Name | Position |
|---|---|
| Mark White | President, Chief Executive Officer, Director |
| David Owens, M.D. | Chief Medical Officer, Director |
| Sam Namiri | Chief Financial Officer |
| Rick Morad | Director |
| Alan Kazden | Director |
| Ben Hu, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| May 16, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Apr 27, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Apr 8, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Feb 4, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Jan 28, 2022 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Jan 3, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 7, 2021 | DRS/A | Draft Registration Statement |
| Nov 2, 2021 | DRS/A | Draft Registration Statement |
| Sep 17, 2021 | DRS | Draft Registration Statement |